These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 26323533)

  • 21. [Utilization of the ES/iPS cell technology for hematopoietic stem cell transplantation].
    Otsu M; Nakauchi H
    Nihon Rinsho; 2012 Apr; 70 Suppl 2():146-50. PubMed ID: 23133943
    [No Abstract]   [Full Text] [Related]  

  • 22. Prospects for pluripotent stem cell therapies: into the clinic and back to the bench.
    Grabel L
    J Cell Biochem; 2012 Feb; 113(2):381-7. PubMed ID: 21928325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Developing Induced Pluripotent Stem Cell-Based Therapy for the Masses.
    Rao MS; Atala A
    Stem Cells Transl Med; 2016 Feb; 5(2):129-31. PubMed ID: 26718646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hope for regenerative treatments: toward safe transplantation of human pluripotent stem-cell-based therapies.
    Kimbrel EA; Lanza R
    Regen Med; 2015; 10(2):99-102. PubMed ID: 25835474
    [No Abstract]   [Full Text] [Related]  

  • 25. To make better therapeutics, companies strive to increase the content of results and get them faster.
    Szpir M
    Biotechniques; 2007 Apr; 42(4 Suppl):S3-5. PubMed ID: 18798735
    [No Abstract]   [Full Text] [Related]  

  • 26. 10 Questions: Clinical Outlook for iPSCs.
    Cell Stem Cell Editorial Team
    Cell Stem Cell; 2016 Feb; 18(2):170-3. PubMed ID: 26849303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug discovery: playing dirty.
    Frantz S
    Nature; 2005 Oct; 437(7061):942-3. PubMed ID: 16222266
    [No Abstract]   [Full Text] [Related]  

  • 28. Patient-Specific Induced Pluripotent Stem Cells for Disease Modeling and Phenotypic Drug Discovery.
    Tang S; Xie M; Cao N; Ding S
    J Med Chem; 2016 Jan; 59(1):2-15. PubMed ID: 26322868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Uncertain translation, uncertain benefit and uncertain risk: ethical challenges facing first-in-human trials of induced pluripotent stem (ips) cells.
    Fung RK; Kerridge IH
    Bioethics; 2013 Feb; 27(2):89-96. PubMed ID: 21726264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stem cell therapies for Parkinson's disease: are trials just around the corner?
    Drouin-Ouellet J; Barker RA
    Regen Med; 2014; 9(5):553-5. PubMed ID: 25372072
    [No Abstract]   [Full Text] [Related]  

  • 31. Immunogenicity of induced pluripotent stem cells.
    Okita K; Nagata N; Yamanaka S
    Circ Res; 2011 Sep; 109(7):720-1. PubMed ID: 21921270
    [No Abstract]   [Full Text] [Related]  

  • 32. Stem cell-based treatment in geographic atrophy: promises and pitfalls.
    Kvanta A; Grudzinska MK
    Acta Ophthalmol; 2014 Feb; 92(1):21-6. PubMed ID: 23890249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Opinion: anticipating change in drug development: the emerging era of translational medicine and therapeutics.
    Fitzgerald GA
    Nat Rev Drug Discov; 2005 Oct; 4(10):815-8. PubMed ID: 16224453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The rejection barrier to induced pluripotent stem cells.
    Balasubramanian S; Kota SK; Valerius MT
    J Am Soc Nephrol; 2011 Sep; 22(9):1583-6. PubMed ID: 21836145
    [No Abstract]   [Full Text] [Related]  

  • 35. "Mouse Clone Model" for evaluating the immunogenicity and tumorigenicity of pluripotent stem cells.
    Zhang G; Zhang Y
    Stem Cell Res Ther; 2015 Dec; 6():255. PubMed ID: 26687081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization and criteria of embryonic stem and induced pluripotent stem cells for a dopamine replacement therapy.
    Cooper O; Parmar M; Isacson O
    Prog Brain Res; 2012; 200():265-76. PubMed ID: 23195423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase 0 trials: an industry perspective.
    Eliopoulos H; Giranda V; Carr R; Tiehen R; Leahy T; Gordon G
    Clin Cancer Res; 2008 Jun; 14(12):3683-8. PubMed ID: 18559583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alan Trounson. Interview by Asher Mullard.
    Trounson A
    Nat Rev Drug Discov; 2012 Jun; 11(7):512. PubMed ID: 22699775
    [No Abstract]   [Full Text] [Related]  

  • 39. Autologous, allogeneic, induced pluripotent stem cell or a combination stem cell therapy? Where are we headed in cartilage repair and why: a concise review.
    Vonk LA; de Windt TS; Slaper-Cortenbach IC; Saris DB
    Stem Cell Res Ther; 2015 May; 6(1):94. PubMed ID: 25976213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene therapy meets stem cells.
    Sandhaus RA
    N Engl J Med; 2012 Feb; 366(6):567-9. PubMed ID: 22316453
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.